WP
SGMT icon

Woodline Partners’s Sagimet Biosciences SGMT Stock Holding History

Woodline Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.23M Hold
1,000,943
– – 0.02% 652
2025
Q4 		$5.93M Sell
1,000,943
-500,414
-33% -$3.6M 0.02% 589
2025
Q3 		$10.3M Sell
1,501,357
-1,051,179
-41% -$8.52M 0.05% 436
2025
Q2 		$19.5M Buy
+2,552,536
New +$10.8M 0.1% 298
2024
Q2 		– Sell
-300,170
Closed -$1.63M – 658
2024
Q1 		$1.63M Buy
300,170
+1
+0% +$7 0.02% 437
2023
Q4 		$1.63M Sell
300,169
-2
-0% -$9 0.02% 389
2023
Q3 		$2.64M Buy
+300,171
New +$4M 0.03% 374

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Woodline Partners's SGMT Position: Q1 2026 in Review

Woodline Partners held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 1,000,943 shares worth $5.23M. The position accounts for 0.02% of the portfolio, ranked #652.

Woodline Partners first reported a position in SGMT in Q3 2023 and has held it in 7 quarters since. The position peaked at $19.5M in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Woodline Partners held 1,000,943 shares of Sagimet Biosciences worth $5.23M as of Q1 2026.
  • Woodline Partners left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up 0.02% of Woodline Partners's portfolio in Q1 2026, its #652 holding.
  • Woodline Partners first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 7 quarters since.
  • Woodline Partners's Sagimet Biosciences position peaked at $19.5M in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.